Clinical trial
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose…
NCT00292760 · Royal Marsden NHS Foundation Trust, Other · Completed
Key facts
| NCT number | NCT00292760 |
|---|---|
| Title | A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion |
| Official title | A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion |
| Lead sponsor | Royal Marsden NHS Foundation Trust, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukaemia |
| Intervention type | Drug |
| Interventions | Alemtuzumab, Methyprednisolone |
| First posted | Feb 16, 2006 |
| Last update posted | Dec 16, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: